Dedicated services to support medical device manufacturers throughout the product lifecycle
ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced the launch of a new Medical Device & Diagnostics Research group focused on the unique requirements of the medical device and diagnostics industry.
The new group combines the medical and regulatory device and diagnostic expertise of Aptiv Solutions, which ICON acquired in 2014, with ICON’s global clinical development and commercialisations solutions. Device and diagnostic manufacturers can now benefit from an expanded suite of services that support the full product lifecycle, including global clinical trial execution, health economics and pricing and market access solutions.
“The device and diagnostic development model can differ significantly from that of pharmaceutical companies, both in complexity and time to market,” commented Elizabeth Thiele, President, ICON Commercialisation & Outcomes. “Operating under specific medical device SOPs and ISO certification, our new Medical Device & Diagnostics Research team has the expertise and flexibility to help manufacturers take time and cost from their development programmes and maximise the value of their products.”
ICON’s Medical Device & Diagnostics Research group will be led by Vicki Anastasi, Vice President, Medical Device & Diagnostic Research, who has over 20 years of medical device and diagnostics experience. The group is comprised of a team of dedicated project managers and clinical operations professionals as well as regulatory and strategic consultants.
About ICON plc
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 83 locations in 38 countries and has approximately 10,600 employees.
ICON Media Contact
Tel: +44 (0) 207 067 0866
This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.